医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

製薬

Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

バイオテクノロジーヘルスケア感染症糖尿病腫瘍学臨床試験製薬遺伝学　 TimeLine: Delivers Another Strong Quarter in FY2022 Q Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions

2023年02月02日

武田薬品工業: パイプラインの進展と2つのターゲットを絞った取得案件により長期的成長に向け加速、2022年度第3四半期も力強い業績を達成

バイオテクノロジーヘルスケア感染症糖尿病腫瘍学臨床試験製薬遺伝学　 TimeLine: ターゲット力強い業績加速武田薬品工業進展

2023年02月02日

Shionogi’s Innovative Antibiotic, FETCROJA® (cefiderocol), Is Now Available in Denmark

Shionogi’s Innovative Antibiotic, FETCROJA® (cefiderocol), Is Now Available in Denmark

バイオテクノロジーヘルスケア感染症臨床試験製薬　 TimeLine: cefiderocol FETCROJA Is Now Available in Denmark Shionogi’s Innovative Antibiotic

2023年02月02日

TURALIO® New Dosing Regimen Now Available in the U.S. for Certain Patients with Tenosynovial Giant Cell Tumor

TURALIO® New Dosing Regimen Now Available in the U.S. for Certain Patients with Tenosynovial Giant Cell Tumor

バイオテクノロジーヘルスケアヘルス一般腫瘍学製薬　 TimeLine: for Certain Patients with Tenosynovial Giant Cell Tumor New Dosing TURALIO

2023年02月01日

BeiGene to Present at Upcoming Investor Conferences

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: BeiGene to Present at Upcoming Investor Conferences

2023年02月01日

Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

バイオテクノロジーヘルスケア製薬　 TimeLine: in China Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta

2023年01月31日

IQVIA in Collaboration with Alibaba Cloud to Deliver Commercial ＆ Clinical Solutions in China

IQVIA in Collaboration with Alibaba Cloud to Deliver Commercial ＆ Clinical Solutions in China

バイオテクノロジーヘルスケアマネージド・ケア医療機器医療管理臨床試験製薬　 TimeLine: Clinical Solutions in China IQVIA in Collaboration with Alibaba Cloud to Deliver Commercial

2023年01月31日

New Promega Chemistry Will Enable Forensic DNA Labs to Solve More Challenging Cold Cases, Sexual Assault Cases

New Promega Chemistry Will Enable Forensic DNA Labs to Solve More Challenging Cold Cases, Sexual Assault Cases

その他ヘルスバイオテクノロジーヘルスケア臨床試験製薬遺伝学　 TimeLine: New Promega Chemistry Will Enable Forensic DNA Labs to Solve More Challenging Cold Cases Sexual Assault Cases

2023年01月31日

Qurient Announces Dosing of First Patient in Q702 in Combination with KEYTRUDA® in a Phase 1b/2 Clinical Study for the Treatment of Patients with Solid Tumors

Qurient Announces Dosing of First Patient in Q702 in Combination with KEYTRUDA® in a Phase 1b/2 Clinical Study for the Treatment of Patients with Solid Tumors

ヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: Clinical Study for the Treatment of Patients with Solid Tumors in a Phase 1b of First Patient in Q702 in Combination with KEYTRUDA Qurient Announces Dosing

2023年01月31日

Berry to Support Asia’s Growing Healthcare Market with New Facility, Center of Excellence in Bangalore, India

Berry to Support Asia’s Growing Healthcare Market with New Facility, Center of Excellence in Bangalore, India

ヘルスケア医療用品病院製薬　 TimeLine: Berry to Support Asia’s Growing Healthcare Market with Center of Excellence in Bangalore India New Facility

2023年01月30日